Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology

Molecular Diagnosis and Therapy

Volumn 11, Issue 5, 2007, Pages 325-335

  Peková, Soňa ^a   Bezdíčková, Ludmila ^b   Smolej, Lukáš ^c   Kozák, Tomáš ^a,b   Hochová, Ivana ^d   Žák, Pavel ^c   Tomšíková, Lucie ^a   Průcha, Miroslav ^a  

^a NA HOMOLCE HOSPITAL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Chronic lymphocytic leukaemia; Diagnostics; Immunoglobulin targets

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUDARABINE; LOCKED NUCLEIC ACID; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; RNA; VINCRISTINE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLONING; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FLUORESCENCE; FOLLOW UP; HUMAN; HYBRIDIZATION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

EID: 35548980505     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256253     Document Type: Article

References (25)

1. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59
2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004: 163-83
3. Rozman C, Brugues R, Montserrat E. About the prognostic value of bone marrow histopathological patterns in B-cell chronic lymphocytic leukaemia. Eur J Haematol 1997; 59: 61-2
4. Matthews C, Catherwood MA, Morris TC, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006; 77: 309-17
5. Mainou-Fowler T, Dignum HM, Proctor SJ, et al. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 2004; 45: 455-62
6. Vinolas N, Reverter JC, Urbano-Ispizua A, et al. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance. Blood Cells 1987; 12: 457-70
7. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-84
8. Vener C, Gianelli U, Cortelezzi A, et al. ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 245-51
9. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-9
10. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-92
11. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005 Dec 15; 106 (13): 4389-96
12. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850-8
13. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433-8
14. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35
15. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia. Blood 2006 Jun 1; 107 (11): 4563-9
16. Pfitzner T, Reiser M, Barth S, et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002; 81: 258-66
17. Pekova S, Markova J, Pajer P, et al. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005; 9: 23-34
18. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87 (12): 4990-7
19. IMGT home page [online]. Available from URL: http://imgt.cines.fr [Accessed 2007 Jul 11]
20. IgBLAST [online]. Available from URL: http://www.ncbi.nlm.nih.gov/igblast [Accessed 2007 Jul 11]
21. Smardova J, Smarda J, Koptikova J. Functional analysis of p53 tumor suppressor in yeast. Differentiation 2005; 73: 261-77
22. Kiyoi H, Naoe T, Yamauchi T, et al. Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT. Leuk Res 1993; 17: 677-84
23. Rada C, Milstein C. The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. Embo J 2001; 20: 4570-6
24. Malec M, van der Velden VH, Bjorklund E, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004; 18: 1630-6
25. European Research Initiative on CLL [online]. Available from URL: http://www.ericll.org/ [Accessed 2007 Sep 17]